|
卡帕塞替尼市场分析报告
|
Prostate Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Geography ... Clinical Trial Phase 1 AstraZeneca capivasertib Clinical Phase II capivasertib + abiraterone CAPItello-281 Clinical ...
Metastatic Breast Cancer Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type ... (40% of HR+), alpelisib's SOLAR-1 validates with fulvestrant; capivasertib's CAPItello-291 combo signals AKT ... in 2024, patents varying regionally; Truqap (capivasertib) contributed USD 400-500 million ...
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018 RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'RAC Alpha SerineThreonine ...
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2018 RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2018 SUMMARY RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC ...
RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019 RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or ...
RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019 RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or ...
RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2019 RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2019 SUMMARY RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 9 ...
RAC Alpha Serine/Threonine Protein Kinase - Pipeline Review, H1 2020 RAC Alpha Serine/Threonine Protein Kinase - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H1 2020'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or ...
RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020 RAC Beta Serine/Threonine Protein Kinase - Pipeline Review, H1 2020 SUMMARY RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules. The ...
Prostate Cancer – Pipeline Insight, 2020 ... Myovant Taiho Oncology Key Products Capivasertib PLX3397 ABX-EGF ODM-201 ...
Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022 ... Ipatasertib Curcumin liposomal Paxalisib Tucidinostat Capivasertib Miransertib Afuresertib Enzastaurin CU 05 API-2 Pravitinib ...
Meningioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major meningioma markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 9.79% during 2024-2034. The meningioma market has been ...
Invasive Ductal Carcinoma Treatment Market Size, Share & Trends Analysis Report By Therapy (Targeted Therapy, Hormonal Therapy), By Type (Hormone Receptor, HER2+), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 ... instance, in March 2024, AstraZeneca’s Truqap (capivasertib) received approval in Japan for use ...
Docetaxel Market Size, Share & Trends Analysis Report By Indication (Breast Cancer, Non-Small Cell Lung Cancer, Hormone Refractory Prostate Cancer, Gastric Adenocarcinoma), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 ... (Daiichi Sankyo), daraxonrasib (Revolution Medicines), capivasertib (AstraZeneca), and others target NSCLC ...
|
|
|